A month af­ter mul­ti-bil­lion dol­lar No­var­tis deal, BeiGene fol­lows up with 're­verse' deal

Just over a month af­ter strik­ing a deal with No­var­tis to bring its PD-1 an­ti­body tislelizum­ab state­side, Chi­na-based BeiGene is mak­ing a sim­i­lar play in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA